Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toremifene in Chemotherapy-Resistant Papillary Carcinoma of the Ovary
NCT00003865Phase 2Withdrawn
- Sponsor
- George Washington University
- Start
- Jul 1999
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of toremifene in ovarian carcinoma (2 arms), sponsored by George Washington University. Primary endpoint: Response Rate. Planned start Jul 1999; status: withdrawn.
02
Drugs
toremifene
03
Conditions
ovarian carcinoma
Beyond the preview
Go deeper on NCT00003865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003865.